board of directors

Background: Nitin has been actively engaged in pharmaceutical product development in the industry since Feb 1998, when (at Elan Pharmaceuticals), he first started studying interactions between powders and polymer surfaces to improve the efficiencies of pulmonary dry powder inhalation products for asthma and COPD. He moved into formulation and process development thereafter and became fully entrenched in pharmaceutical dosage form development. He has actively contributed to various drug delivery products from new chemical entities to drug delivery applications for known molecules. In 2006, he started working on a transdermal product for post- operative pain at ALZA Corporation. He led the development of the next-generation version of IONSYS, a drug-device combination transdermal product. He believed in the technology and the value of the product, so when the company terminated the program he got together with outside investors and created Incline Therapeutics to get this product approved and to the market. The product eventually succeeded in securing approval in the US and the European Union.

Background: Prof. Mitragotri has made groundbreaking contributions to the field of biological barriers and drug delivery. His research has advanced fundamental understanding of biological barriers and has led to the development of new materials as well as technologies for diagnosis and treatment of various ailments including diabetes, cardiovascular diseases, skin diseases and infectious diseases, among others. Many of his technologies have advanced to human clinical studies and products. At the same time, fundamental understanding developed through his research has advanced the understanding of the biology of barriers in the human body. Currently, he is employed as the Hiller Professor of Bioengineering and Hansjorg Wyss Professor of Biologically Inspired Engineering at Harvard John A. Paulson School of Engineering and Applied Sciences. His research is focused on transdermal, oral and targeted drug delivery systems. He is an elected member of the NAE and NAM, and an elected fellow of NAI, AAAS, CRS, BMES, AIMBE, and AAPS. 

Background: Dr. Keyser is a veteran of the pharmaceutical industry with 40 years of leadership experience in developing and commercializing new medical therapies. He has invented products leading to significant improvements in patient care and has numerous patents issued by the USPTO in healthcare. He has a track record of success in developing new companies from start-up, through IPO and M&A exits. Dr. Keyser co-founded Renibus Therapeutics, a company developing novel therapies for the diagnosis, treatment and prevention of kidney disease. He is a member of the Renibus Board of Directors and Board Secretary. He is the President and Chief Operating Officer for the company. He is currently serving as the Chairman of the Board for Lantern Pharma. Dr. Keyser co-founded ZS Pharma acquired by Astra Zeneca for $2.7 Billion. While at ZS Pharma he was a member of ZS Pharma’s Board of Directors and the Chief Operating Officer for the company. Dr. Keyser was the inventor of the Mucinex product line for Adams Respiratory Therapeutics. He developed

and executed the R&D and Regulatory strategy for Adams Respiratory Therapeutics as Vice President of Development and Regulatory Affairs. Adams Respiratory Therapeutics was acquired by Reckitt Benckiser for $2.3 Billion. He was previously employed as Chief Compliance Officer & Vice President Regulatory Affairs, Encysive Pharmaceuticals, Vice

President Technical & Regulatory Affairs, Medeva Americas, Sr. Director Regulatory Affairs, Marion Merrell Dow and Regulatory Principal, Abbott Laboratories. Dr. Keyser received his Pharmacy degree from Creighton University, a Juris Doctorate from Creighton University, a MPA from the University of Missouri-Kansas City and a PhD in Economics from The University of Texas at Dallas.